# Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

> **NCT05376579** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 134 (actual)

## Conditions studied

- Active Secondary Progressive Multiple Sclerosis

## Interventions

- **OTHER:** siponimod

## Key facts

- **NCT ID:** NCT05376579
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-17
- **Primary completion:** 2025-07-22
- **Final completion:** 2025-07-22
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05376579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05376579, "Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05376579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*